药理学,计算和机械学的洞察力,探讨三胺在向抗药性癌症中的作用
Md Sadique Hussain1, Somdutt Mujwar2, M Arockia Babu3
1Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, 248007, India.
一种天然化合物托利德 (Triptolide) 通过专门准癌细胞,显示出对抗抗药性癌症的前途. 它克服了治疗耐药性,并增强了传统疗法,尽管毒性和输送挑战仍然存在.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 自然产品 化学 化学
背景情况:
- 特里普托利德是来自Tripterygium wilfordii的双类物质,是对抗耐药癌症的潜在药物.
- 它通过抑制RNA聚合酶II,热冲击蛋白 (HSP70,HSP90) 和NF-kB信号传递来表现出抗瘤活性.
研究的目的:
- 审查ptolide 的抗瘤活动和机制.
- 讨论其在克服癌症耐受机制和增强常规疗法的潜力.
- 解决临床应用中的挑战,并通过药物输送系统探索解决方案.
主要方法:
- 在triptolide的临床前和临床研究的文献综述.
- 对三类分子标和信号通路的分析 (例如,RNA聚合酶II,HSPs,NF-kB,PI3K/AKT/mTOR,PARP).
- 对抗癌症耐受机制 (排气,EMT,CSC) 的托利德疗效的评估.
主要成果:
- 特里普托利德专门针对癌细胞,不影响正常细胞,并且在胰腺,乳腺和肺癌中表现出有效性.
- 它可以抵消癌症耐受性机制,如排泄上调,上皮-介质细胞过渡和癌症干细胞.
- 特里普托利德调节关键信号通路,并增强常规疗法的疗效,其衍生物Minnelide的临床前和早期临床数据很有希望.
结论:
- 特里普托利德是一种有前途的精准医学工具,用于克服癌症治疗耐受性.
- 药物输送系统正在开发中,以减轻三类的毒性和生物可用性问题.
- 需要进一步的研究来优化Minnelide的剂量,输送和临床使用的安全性.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
相关概念视频
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
